Past Program: September
8, 2000
ADVANCED PEDIATRIC PSYCHOPHARMACOLOGY
RECENT
ADVANCES,
CLINICAL
UPDATES,
SAFETY
CONCERNS
An in-depth seminar with Doug Lee, MD
6:30 - 10:00 pm September 8, 2000 Emory Conference Center Atlanta, Georgia
Sponsored by the Georgia Council on Child and Adolescent Psychiatry
This seminar is an exciting opportunity for Psychiatrists, Pediatricians and Family Physicians to learn from Doug Lee, MD, Emory University's Director of Pediatric Psychopharmacology, about the most recently introduced medications for the treatment of behavior disorders and mental illness in our Pediatric Population.Program
Friday evening, September 8, 2000
6:30 Registration and Social Hour
7:00 Dinner and Lecture:
Advances
in Pediatric Psychopharmacology
Doug Lee, MD
9:30 Case Presentations & Open Discussion
Participants of the seminar will have an opportunity to present cases or perplexing psychopharmacology issues to Dr. Lee.
This program has been approved for 3 hours of CME credit by the Georgia Psychiatric Physicians Association
Doug Lee, MD
Dr. Lee is the Director of the Pediatric Psychopharmacology Program at Emory University Medical Center and of Psychiatry at the Marcus Institute in Atlanta. He has been involved in the treatment of childhood and adolescent Psychiatric Disorders at Bellevue Hospital/New York University School of Medicine, Harvard Medical School and Emory University School of Medicine. He has been awarded the Outstanding Educator Award for the Department of Psychiatry at Emory for 1996, 1998 and 1999. He was recipient of the Wyeth-Ayerst Faculty Development Award in 2000. Dr. Lee has authored numerous important publications in the field of child and adolescent psychiatry, especially psychopharmacology. He is an active contributor to the literature focused on Developmental Disabilities. He has been an invited speaker at national and international conferences including the Annual Emory Autism Conference, the Intercontinental Primary Medical Society and the Marcus Institute Conference.
This seminar is supported in part by a grant from the American Academy of Child and Adolescent Psychiatry and Solvay Pharmaceuticals.